Table 1.
Demographic and tumor information, and clinical predictors for 16 patients with newly diagnosed GB
| Category | Category | Value |
|---|---|---|
| Age at diagnosis (years) | NA | 59 (55–67) |
| Sex | Male | 10 (62 %) |
| Female | 6 (38 %) | |
| Extent of resection | Sub total resection | 5 (31.3 %) |
| Gross total resection | 5 (31.3 %) | |
| Near total resection | 4 (25 %) | |
| Biopsy/Partial resection | 2 (12.5 %) | |
| EGFR vIII status | Positive | 9 (56.3 %) |
| Negative | 6 (37.5 %) | |
| No data | 1 (6.25 %) | |
| Ki67 proliferation (percent of cells in 10 high power fields) |
Average | 28 % |
| Range | 5–70 % | |
| NR | 2% | |
| MGMT (methylguanine-DNA-methyltransferase) methylation status |
Methylated | 3 (18.75 %) |
| Not methylated | 12 (75 %) | |
| NP | 1 (6.25 %) | |
| KPS (Karnofsky performance status) | Pre-op | 88.8 (90, 90) |
| ECOG (Eastern Cooperative Oncology Group) performance status |
Pre-op | 0.75 (0–3.0) |
| RPA (Recursive partitioning analysis) | Pre-op | 4.19 (4.0–5.0) |
| Growth post-operatively or during CRT | Growth | 7 (43.75 |
| No growth | 9 (56.25) | |
| Therapy during CRT | Avastin | 1 (6 %) |
| Steroids | 1 (6 %) | |
| No additional therapy | 14 (88 %) | |
| Additional treatments after recurrence | Surgery | 6 (20.7 %) |
| None | 5 (17.2 %) | |
| Avastin | 5(17.2 %) | |
| EGFR vIII vaccine | 5(17.2 %) | |
| Chemotherapy | 5(17.2 %) | |
| CAR-T cells | 2 (7.9 %) | |
| Novocure/optune | 1 (3.7 %) | |
| Neutrophil count (thousand per μL blood) | Pre-op | 7.9 (4.5, 10.1) |
| At start of CRT | 7.0 (4.1, 10.1) | |
| At end of CRT | 3.9 (1.9, 5.9) | |
| Neutrophil:lymphocyte ratio | Pre-op | 5.2 (2.1, 6.9) |
| At start of CRT | 5.33 (2.1, 6.7) | |
| At end of CRT | 5.03 (2.6, 6.8) |
Values shown are medians with interquartile range (IQR) or counts with percentages
NP not performed because there were either too many small groups or not enough samples, NR not reported